The immunogenicity and protection efficacy evaluation of mRNA vaccine candidate for severe fever with thrombocytopenia syndrome in mice
PLOS Neglected Tropical Diseases · 30.04.2025 · 19 (4) · e0012999
DOI: 10.1371/journal.pntd.0012999 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 30.04.2025. Verfasst von Da-Eun Jeong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, Republic of Korea. Hauptthemen laut MEDLINE: Severe Fever with Thrombocytopenia Syndrome, Phlebovirus, Viral Vaccines, Immunogenicity, Vaccine. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tick-borne viral pathogen that causes Severe fever with thrombocytopenia syndrome (SFTS) in humans with a high fatality rate. Currently, there are no approved antivirals or vaccines against SFTSV. The envelope protein of SFTSV, which consists of two domains, Gn and Gc, has been investigated as a target antigen for the development of SFTSV vaccines. Here, we used an mRNA platform to develop an effective and safe SFTSV vaccine. Our mRNA vaccine candidate harbored an equal number of mRNAs individually encoding the full-length SFTSV Gn or Gc domain. These mRNAs were produced using a 5′ cap, SmartCap, by in vitro transcription and then packaged with an ionizable lipid nanoparticle platform, called STLNP. Robust expression of these Gn and Gc antigens was observed when human 293 T cells were transfected with the SFTSV mRNA formulation. When mice were immunized with our SFTSV vaccine candidate, the collected serum displayed strong immunogenicity and in vitro neutralization activity against SFTSV. Thus, the immunized mice showed complete protection with a lethal dose of SFTSV, without any pathological traces of SFTSV infection-mediated tissue damage. Thus, our mRNA vaccine platform is a promising SFTS vaccine candidate for clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Korea Zoonosis Research Institute, Jeonbuk National University, Iksan, Republic of Korea.
- Vernagen LLC, Tucker, Georgia, United States of America.
ORCID-Profile: Baek Kim, Jun-Gu Kang
Zitieren
APA
Jeong, D. E., Yoon, J., Kim, B., & Kang, J. G. (2025). The immunogenicity and protection efficacy evaluation of mRNA vaccine candidate for severe fever with thrombocytopenia syndrome in mice. PLOS Neglected Tropical Diseases, 19(4), e0012999. https://doi.org/10.1371/journal.pntd.0012999
Vancouver
Jeong DE, Yoon J, Kim B, Kang JG. The immunogenicity and protection efficacy evaluation of mRNA vaccine candidate for severe fever with thrombocytopenia syndrome in mice. PLOS Neglected Tropical Diseases. 2025;19(4):e0012999. doi:10.1371/journal.pntd.0012999
BibTeX
@article{Jeong2025,
author = {Jeong, Da-Eun and Yoon, Jack and Kim, Baek and Kang, Jun-Gu},
title = {The immunogenicity and protection efficacy evaluation of mRNA vaccine candidate for severe fever with thrombocytopenia syndrome in mice},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
volume = {19},
number = {4},
pages = {e0012999},
doi = {10.1371/journal.pntd.0012999}
}
EUVIMED